皮肤性病威廉亚洲博彩公司

订阅

MedSci主页 / 所有栏目 / 皮肤性病威廉亚洲博彩公司

系统Janus激酶抑制剂治疗特应性皮炎专家共识

2022-09-25 中国中西医结合学会皮肤性病专业委员会 实用皮肤病学杂志

特应性皮炎Janus激酶抑制剂

近年来,国内外关于特应性皮炎(atopic dermatitis,AD)的研究取得了很多进展,新型药物层出不穷,为AD的治疗提供了多种选择。其中Janus激酶(Janus kinase,JAK)抑制剂

中文标题：

系统Janus激酶抑制剂治疗特应性皮炎专家共识

发布机构：

中国中西医结合学会皮肤性病专业委员会

发布日期：

2022-09-25

简要介绍：

近年来,国内外关于特应性皮炎(atopic dermatitis,AD)的研究取得了很多进展,新型药物层出不穷,为AD的治疗提供了多种选择。其中Janus激酶(Janus kinase,JAK)抑制剂以其多靶点作用、快速起效的特点为中重度AD患者带来了新的希望。目前已经有多种口服JAK抑制剂在国内外上市，但我国尚缺乏合理使用口服JAK抑制剂治疗AD的规范和标准,很多医师对JAK抑制剂的认识尚不充分。本共识以国内外口服JAK抑制剂的临床证据为基础,结合临床专家的实践经验编制而成，旨在指导口服JAK抑制剂在AD治疗中的合理应用,提高疗效,减少不良反应。

相关资料下载：
[AttachmentFileName(sort=1, fileName=系统Janus激酶抑制剂治疗特应性皮炎专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d26bc1c002e1a5c5, title=系统Janus激酶抑制剂治疗特应性皮炎专家共识, enTitle=, guiderFrom=实用皮肤病学杂志, authorId=0, author=, summary=近年来,国内外关于特应性皮炎(atopic dermatitis,AD)的研究取得了很多进展,新型药物层出不穷,为AD的治疗提供了多种选择。其中Janus激酶(Janus kinase,JAK)抑制剂, cover=https://img.medsci.cn/202201010/1665366553906_5579292.jpg, journalId=0, articlesId=null, associationId=175, associationName=中国中西医结合学会皮肤性病专业委员会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Sep 25 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">近年来,国内外关于特应性皮炎(atopic dermatitis,AD)的研究取得了很多进展,新型药物层出不穷,为AD的治疗提供了多种选择。其中Janus激酶(Janus kinase,JAK)抑制剂以其多靶点作用、快速起效的特点为中重度AD患者带来了新的希望。目前已经有多种口服JAK抑制剂在国内外上市，但我国尚缺乏合理使用口服JAK抑制剂治疗AD的规范和标准,很多医师对JAK抑制剂的认识尚不充分。本共识以国内外口服JAK抑制剂的临床证据为基础,结合临床专家的实践经验编制而成，旨在指导口服JAK抑制剂在AD治疗中的合理应用,提高疗效,减少不良反应。</span></p>, tagList=[TagDto(tagId=13273, tagName=特应性皮炎), TagDto(tagId=89959, tagName=Janus激酶抑制剂)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤性病, tenant=100), CategoryDto(categoryId=85, categoryName=威廉亚洲博彩公司 &解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2911, appHits=97, showAppHits=0, pcHits=529, showPcHits=2814, likes=4, shares=8, comments=6, approvalStatus=1, publishedTime=Fri Oct 14 09:51:00 CST 2022, publishedTimeString=2022-09-25, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Oct 10 09:48:42 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Fri Jan 05 10:24:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=系统Janus激酶抑制剂治疗特应性皮炎专家共识.pdf)])
系统Janus激酶抑制剂治疗特应性皮炎专家共识.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2101361, encodeId=cc6a21013611e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5b1958930, createdName=panyulongcool, createdTime=Fri Nov 18 17:17:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094514, encodeId=6d8a2094514c2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Tue Oct 18 16:26:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093761, encodeId=8ac12093e618c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Fri Oct 14 12:17:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093741, encodeId=b7172093e4171, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3b8358257, createdName=ms7000001349198488, createdTime=Fri Oct 14 09:55:42 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-11-18 panyulongcool

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2101361, encodeId=cc6a21013611e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5b1958930, createdName=panyulongcool, createdTime=Fri Nov 18 17:17:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094514, encodeId=6d8a2094514c2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Tue Oct 18 16:26:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093761, encodeId=8ac12093e618c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Fri Oct 14 12:17:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093741, encodeId=b7172093e4171, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3b8358257, createdName=ms7000001349198488, createdTime=Fri Oct 14 09:55:42 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-18 124d4decm76暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2101361, encodeId=cc6a21013611e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5b1958930, createdName=panyulongcool, createdTime=Fri Nov 18 17:17:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094514, encodeId=6d8a2094514c2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Tue Oct 18 16:26:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093761, encodeId=8ac12093e618c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Fri Oct 14 12:17:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093741, encodeId=b7172093e4171, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3b8358257, createdName=ms7000001349198488, createdTime=Fri Oct 14 09:55:42 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-14 zwddoctor

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2101361, encodeId=cc6a21013611e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5b1958930, createdName=panyulongcool, createdTime=Fri Nov 18 17:17:58 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094514, encodeId=6d8a2094514c2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Tue Oct 18 16:26:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093761, encodeId=8ac12093e618c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Fri Oct 14 12:17:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093741, encodeId=b7172093e4171, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3b8358257, createdName=ms7000001349198488, createdTime=Fri Oct 14 09:55:42 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-14 ms7000001349198488

    牛

    0

相关威廉亚洲博彩公司

2021 JDA 特应性皮炎管理临床实践威廉亚洲博彩公司 英文版

日本皮肤病协会(JDA,Japanese Dermatological Association) · 2022-08-22

中重度特应性皮炎系统药物达标治疗专家指导建议

北京大学第一医院皮肤科国家皮肤病与免疫疾病临床医学中心 · 2022-06-17

2021 JDA威廉亚洲博彩公司 ：特应性皮炎—概要

日本皮肤病协会(JDA,Japanese Dermatological Association) · 2022-09-02

中重度特应性皮炎系统药物达标治疗 专家指导建议

中国皮肤性病相关专家小组（统称） · 2022-08-01

2021 JDA临床实践威廉亚洲博彩公司 ：特应性皮炎的管理

日本皮肤病协会(JDA,Japanese Dermatological Association) · 2022-08-22

2022 欧洲威廉亚洲博彩公司 ：特应性湿疹（皮炎）—第Ⅰ部分：系统治疗

欧洲皮肤病学论坛(EDF,European Dermatology Forum) · 2022-08-15